Atorvastatin to Reduce Risk of Anthracycline-Associated Cardiac Dysfunction
Anthracyclines are used to treat a variety of cancers, but treatment may be limited by cardiac toxicity. JAMA Executive Editor Gregory Curfman, MD, discusses a new clinical trial on the use of atorvastatin to prevent anthracycline-induced cardiac toxicity with authors Tomas Neilan, MD, MPH, and Marielle Scherrer-Crosbie, MD, PhD. Related Content: Atorvastatin for Anthracycline-Associated Cardiac Dysfunction (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - August 8, 2023 Category: General Medicine Authors: JAMA Network Source Type: podcasts
Wealth Shock and Mortality, Atorvastatin for PCI, BP Targets in Diabetes, Neonatal Abstinence Syndrome, and more
Editor's Summary by Edward H. Livingston, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the April 3, 2018, issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - April 3, 2018 Category: General Medicine Authors: JAMA Network Source Type: podcasts
ESC on anticoagulants; FDA on Liptruzet; Midei suit; MitraClip
ESC on anticoagulants; FDA approves atorvastatin/ezetimibe combo (Liptruzet) ; Midei suit settled; MitraClip (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - May 10, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#183: Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin
Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 22, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#141: Pfizer stops promoting Lipitor in US; moderate coffee intake protects against stroke; MagnaSafe: MRI with pacers, ICDs: Safe, a few minor issues; FAME II: FFR pinpoints stable CAD patients who do worse with OMT; whistleblower suit implicates Nissen
Pfizer stops promoting Lipitor in US; moderate coffee intake protects against stroke; MagnaSafe: MRI with pacers, ICDs: Safe, a few minor issues; FAME II: FFR pinpoints stable CAD patients who fare worse with OMT; whistleblower suit implicates Nissen, Cle (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - May 18, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#120: CardioMEMS implantable PA-pressure monitor rejected by FDA; iPad app streams real-time data; bleeding in AF: European consensus; concern over Pfizer's Lipitor deals; cardiologists support elective PCI without on-site CABG: Survey
CardioMEMS implantable PA-pressure monitor rejected by FDA; iPad app streams real-time data; bleeding in AF: European consensus; concern over Pfizer's Lipitor deals; cardiologists support elective PCI without on-site CABG: Survey (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - December 16, 2011 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#119: Stents, ICDs, inappropriate? Then CMS won't pay; FDA investigating serious bleeding events with dabigatran; Generic atorvastatin now in US; CV risk negligible with COX-2 inhibitors but AF a possible concern; noncardiac chest pain
Stents, ICDs, inappropriate? Then CMS won't pay; FDA investigating serious bleeding events with dabigatran; Generic atorvastatin now in US; CV risk negligible with COX-2 inhibitors but AF a possible concern; noncardiac chest pain (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - December 9, 2011 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
